Organogenesis Holdings Inc. ( ORGO ) NASDAQ Capital Market

Cena: 4.88 ( 9.06% )

Aktualizacja 08-22 21:58
NASDAQ Capital Market
Branża: Drug Manufacturers - Specialty & Generic
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Organogenesis Holdings Inc., firma medycyny regeneracyjnej rozwija, produkuje i komercjalizuje roztwory zaawansowanej opieki ran oraz rynków medycyny chirurgicznej i sportowej w Stanach Zjednoczonych. Zaawansowane produkty do pielęgnacji ran firmy obejmują powinowactwo, ranę błony owodniowej, w której zachowują się żywotne czynniki wzrostu/cytokiny, oraz białka ECM w natywnej tkance; ApliGraf, bioinżynieria żywych terapii komórkowej, która wytwarza spektrum cytokin i czynników wzrostu; Dermagraft, produkt bioinżynierowy, który produkuje ludzki kolagen, ECM, białka i cytokiny; Nushield, tkanka pokrywająca ranę obejmuje zarówno błony płodowe, jak i naczyniowe dla warstwy gąbczastej/pośredniej nienaruszonej; Puraply, bariera przeciwdrobnoustrojowa, która umożliwia zgodność i drenaż płynu; i Novachor, rana błony owodniowej, w której zachowane są żywotne komórki, czynniki wzrostu/cytokiny i białka ECM. Produkty medycyny chirurgicznej i sportowej obejmują nukel, odwodnioną tkankę łożyska chirurgicznie zastosowaną do tkanki docelowej w celu wsparcia rodzimych gojenia; Renu, kapryśne zawiesinę stosowane do nasycania tkanek miękkich; oraz Fiberos i OCMP stosowane jako wypełniacz z pustką kostną przede wszystkim w zastosowaniach ortopedycznych i neurochirurgicznych. Produkty rurociągowe firmy obejmują Puraply XT i Puraply MZ do leczenia ran przewlekłych, ostrych i otwartych; Puraforce, bioinżynieria ścisła kolagen świńska do stosowania w zastosowaniach wzmacniających tkankę miękką; i transcyte, bioinżynieryjna tkanka do leczenia oparzeń grubości częściowej. Obsługuje szpitale, centra opieki ran, obiekty rządowe, centra usług ambulatoryjnych i biuro lekarzy za pośrednictwem sprzedaży bezpośredniej i niezależnych agencji. Firma została założona w 1985 roku i ma siedzibę w Canton, Massachusetts.

Informacje o spółce:
Sektor: Zdrowie
Branża: Drug Manufacturers - Specialty & Generic
Zatrudnienie: 862
Giełda: NASDAQ Capital Market
Ilość akcji w obrocie: 59.8371
Ilość akcji: Brak danych
Debiut giełdowy: 2017-01-05
WWW: https://organogenesis.com
CEO: Mr. Gary S. Gillheeney Sr.
Adres: 85 Dan Road
Siedziba: 02021 Canton
ISIN: US68621F1021
Wskaźniki finansowe
Kapitalizacja (USD) 618 432 750
Aktywa: 446 296 000
Cena: 4.88
Wskaźnik Altman Z-Score: 2.9
Umiarkowany (ryzyko bankructwa średnie)
Dywidenda: 0
P/E: -34.8
Ilość akcji w obrocie: 60%
Średni wolumen: 869 714
Ilość akcji 126 858 000
Wskaźniki finansowe
Przychody TTM 455 038 000
Zobowiązania: 167 749 000
Przedział 52 tyg.: 2.455 - 6.71
Piotroski F-Score: 6
Umiarkowany (średnia jakość finansowa)
EPS: -0.1
P/E branży: 22.5
Beta: 1.598
Raport okresowy: 2025-11-05
WWW: https://organogenesis.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Ms. Lori H. Freedman B.A., Esq., J.D. Chief Administrative & Legal Officer 844 256 1967
Mr. Patrick Bilbo Chief Operating Officer 806 494 1962
Mr. Brian Grow Chief Commercial Officer 724 122 1977
Mr. David C. Francisco Chief Financial Officer 628 519 1966
Mr. Gary S. Gillheeney Sr. President, Chief Executive Officer, Chair of the Board 1 749 513 1955
Mr. William R. Kolb CPA Secretary 0 0
Mr. Robert Cavorsi Vice President of Strategy 0 1979
Lista ETF z ekspozycją na akcje Organogenesis Holdings Inc.
Symbol ETF Ilość akcji Wartość
XS5E.DE 3 276 015 13 253 886
D5BM.DE 3 276 015 13 253 886
XSPX.L 3 276 015 1 146 929 616
XSPU.L 3 276 015 15 135 190
XSXD.L 3 276 015 15 135 190
XS5G.L 3 276 015 11 469 296
IWM 1 715 525 7 925 723
IWO 619 663 2 862 843
DFAT 464 973 2 148 175
VTWO 347 743 1 272 739
SCHA 327 989 1 512 554
DFAS 323 116 1 492 795
VHT 172 975 633 088
EES 169 964 785 233
FESM 162 671 816 608
IWC 156 485 722 961
AVSC 143 357 668 043
PRFZ 117 399 547 079
R2SC.L 110 327 389 597
R2US.L 110 327 514 123
ZPRR.DE 110 327 450 218
DFAC 106 372 491 438
GSSC 75 363 336 118
VTWG 60 758 222 374
SCHB 45 609 211 737
RSSL 34 483 159 311
IWV 31 024 143 332
XRS2.DE 27 459 111 090
XRSG.L 27 459 9 613 261
XRSU.L 27 459 126 859
DFAU 22 383 103 409
XSU.TO 12 224 78 722
DCOR 9 772 45 146
AVUS 9 486 44 204
ISCV 8 436 38 976
ISCG 8 211 37 937
OMFS 7 485 34 880
UWM 6 912 31 933
URTY 5 721 26 431
VTHR 5 493 20 104
FLQS 5 452 25 406
ISCB 3 364 15 541
SAGP 178 0
HDG 83 383
DXUV 32 147
RTYS.L 0 29 943
PZW.TO 0 2 562
SC0K.DE 0 26 236
Wiadomości dla Organogenesis Holdings Inc.
Tytuł Treść Źródło Aktualizacja Link
Organogenesis Holdings Inc. (ORGO) Q1 2025 Earnings Call Transcript Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Gary Gillheeney - President and Chief Executive Officer David Francisco - Chief Financial Officer Conference Call Participants Aaron Wukmir - Lake Street Capital Markets Ryan Zimmerman - BTIG Ross Osborn - Cantor Fitzgerald Operator Welcome, ladies and gentlemen, to the First Quarter 2025 Earnings Conference Call for Organogenesis Holdings Inc. [Operator Instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A, Risk Factors, of the company's most recent annual report and its subsequently filed quarterly reports. seekingalpha.com 2025-05-11 14:14:18 Czytaj oryginał (ang.)
Organogenesis (ORGO) Reports Q1 Loss, Lags Revenue Estimates Organogenesis (ORGO) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of $0.04. This compares to loss of $0.02 per share a year ago. zacks.com 2025-05-08 23:10:44 Czytaj oryginał (ang.)
Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2025. globenewswire.com 2025-05-08 20:05:00 Czytaj oryginał (ang.)
Burn Care Market worth $3.35 billion by 2030 with 5.6% CAGR | MarketsandMarkets™ DELRAY BEACH, Fla., May 2, 2025 /PRNewswire/ -- The global Burn Care Market, valued at US$2.46 billion in 2024, is forecasted to grow at a robust CAGR of 5.6%, reaching US$2.55 billion in 2025 and an impressive US$3.35 billion by 2030. This market is experiencing consistent growth due to several key factors. The number of burn injuries is rising due to factors such as industrial accidents, domestic fires, and other hazards. Furthermore, advancements in treatment technologies and increased awareness and education about burn care contribute to this trend. Additionally, supportive government initiatives play a significant role in market development. The demand for effective burn treatments is rising as the global population ages. Older individuals are more susceptible to slow-healing wounds and burn complications, which, in turn, increases the need for advanced burn care products. Moreover, technological advancements in burn treatment—including innovative burn dressings, biologics, and advanced burn wound assessment devices—enhance treatment efficiency and effectiveness. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=247121470 Browse in-depth TOC on "Burn Care Market" 345 - Tables 45 - Figures 302 - Pages By Based on products, the burn care market is categorized into five segments: advanced burn dressings, burn wound therapy devices, biologics, traditional burn care products, and other burn care products. Among these, the biologics segment is expected to register the highest CAGR during the forecast period. This growth is driven by the rising demand for advanced and effective treatment options for deep and complex burns. Biologics provide targeted healing, minimize long-term complications, and promote tissue regeneration, making them particularly suitable for treating severe burns. The increasing acceptance of these products among healthcare professionals and ongoing innovations in regenerative medicine are contributing to the strong and sustained growth of the biologics segment. By Based on burn degree, the burn care market is divided into first-degree burns (minor burns), second-degree burns (partial-thickness burns), and third-degree burns (full-thickness burns). Of these, the second-degree burns segment accounted for the largest market share of the burn care market in 2024. This is largely because partial-thickness burns occur more frequently. These burns tend to destroy the epidermis and dermis; as such, they require the application of advanced burn care products, which drives consistent demand in this segment. By geography, the market for burn care is divided into five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the burn care market in 2024 with the largest market share. This is primarily because countries like the US and Canada have well-developed healthcare facilities, supporting widespread access to advanced burn care products and treatments. The region also experiences a high rate of burn injuries. The availability of key players and constant investment in research & development further consolidate North America's position in the burn care market. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=247121470 The major players operating in this market are Smith+Nephew (UK), Mölnlycke Health Care AB (Sweden), Cardinal Health Inc. (US), Integra LifeSciences Holdings Corporation (US), ConvaTec Group Plc (UK), Coloplast Group (Denmark), Solventum Corporation (US), Essity Aktiebolag (Sweden), PAUL HARTMANN AG (Germany), and Organogenesis Holdings Inc. (US). SMITH+NEPHEW (UK) Smith+Nephew is distinguished by its advanced wound care solutions and robust research and development capabilities, enabling it to provide effective burn care products. Mölnlycke Health Care AB has solidified its market position through strategic partnerships. Cardinal Health Inc. utilizes its extensive distribution network and diverse product line to reach a wide range of healthcare facilities, thereby increasing its share in the burn care market. Integra LifeSciences Holdings Corporation is recognized for its broad range of biologics that offer crucial support for severe burns. ConvaTec Group Plc has strengthened its market presence through global expansion and strategic acquisitions. MOLNLYCKE HEALTH CARE AB (SWEDEN): Mölnlycke Health Care AB also boasts a comprehensive product portfolio in the advanced wound care market. The company's leading position in this sector is largely due to its robust global sales and distribution network, which allows it to effectively market its products in various countries. Mölnlycke primarily utilizes inorganic strategies, such as partnerships, to maintain its market position. For example, in May 2024, the company formed a new partnership with the Phoenix Society, a burn survivor organization in the US. Through this collaboration, Mölnlycke will support the Phoenix Society's initiatives with its extensive range of burn care solutions For more information, Inquire Now! Related Reports: Wound Care Biologics Market Advanced Wound Care Market Point of Care Diagnostics Market Wound Care Market Point of Care Molecular Diagnostics Market Get access to the latest updates on Burn Care Companies and Burn Care Market Size About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg https://www.prnewswire.com 2025-05-02 14:15:00 Czytaj oryginał (ang.)
Organogenesis Supports CMS' Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness Organogenesis recommends CMS also implement an integrated coverage and payment policy Organogenesis recommends CMS also implement an integrated coverage and payment policy globenewswire.com 2025-04-11 20:05:00 Czytaj oryginał (ang.)
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025 CANTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that first quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, May 8th. globenewswire.com 2025-04-07 20:05:00 Czytaj oryginał (ang.)
Organogenesis Holdings Inc. (ORGO) Q4 2024 Earnings Call Transcript Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Gary S. Gillheeney, Sr. – President and Chief Executive Officer Dave Francisco – Chief Financial Officer Conference Call Participants Brooks O'Neil – Lake Street Capital Markets Ross Osborn – Cantor Fitzgerald Ryan Zimmerman – BTIG Operator Please standby. seekingalpha.com 2025-02-27 22:27:37 Czytaj oryginał (ang.)
Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results CANTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2024. globenewswire.com 2025-02-27 18:05:00 Czytaj oryginał (ang.)
Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025 CANTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2024 financial results will be reported after the market closes on Thursday, February 27th. globenewswire.com 2025-01-27 09:30:00 Czytaj oryginał (ang.)
Organogenesis Expands Manufacturing Capacity to Support Future Growth CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island. globenewswire.com 2024-11-22 18:05:00 Czytaj oryginał (ang.)
Organogenesis Commends Final LCDs Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination globenewswire.com 2024-11-15 11:25:00 Czytaj oryginał (ang.)
Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Transcript Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Chair Dave Francisco - Chief Financial Officer Conference Call Participants Ross Osborne - Cantor Fitzgerald Ryan Zimmerman - BTIG Operator Please stand by. Welcome ladies and gentlemen to the Third Quarter of Fiscal Year 2024 Earnings Conference Call for Organogenesis Holdings Inc. At this time, all participants are placed in listen-only mode. seekingalpha.com 2024-11-13 01:02:13 Czytaj oryginał (ang.)
Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock Net proceeds to fund the Company's strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchases Net proceeds to fund the Company's strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchases globenewswire.com 2024-11-12 18:01:00 Czytaj oryginał (ang.)
Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis CANTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the favorable outcome of the interim analysis of its second Phase 3 randomized control trial of ReNu, a cryopreserved amniotic suspension allograft (ASA), for the management of symptoms associated with knee osteoarthritis (OA). globenewswire.com 2024-11-11 19:05:00 Czytaj oryginał (ang.)
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024 CANTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2024 financial results will be reported after the market closes on Tuesday, November 12th. globenewswire.com 2024-10-16 11:30:00 Czytaj oryginał (ang.)
Organogenesis (ORGO) Shows Fast-paced Momentum But Is Still a Bargain Stock If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Organogenesis (ORGO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen. zacks.com 2024-10-15 13:51:23 Czytaj oryginał (ang.)
Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers CANTON, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the publication of “Dehydrated Amnion Chorion Membrane Versus Standard of Care for Diabetic Foot Ulcers: A Randomised Controlled Trial” in the Journal of Wound Care. globenewswire.com 2024-10-01 20:05:00 Czytaj oryginał (ang.)
Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September CANTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the following upcoming investor conferences: globenewswire.com 2024-09-04 20:05:00 Czytaj oryginał (ang.)
Organogenesis Holdings, Inc. (ORGO) Q2 2024 Earnings Call Transcript Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Chair Dave Francisco - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Brooks O'Neill - Lake Street Drew Ranieri - Morgan Stanley Matthew Park - Cantor Fitzgerald Operator Please stand by. Welcome ladies and gentlemen to the Second Quarter 2024 Earnings Conference Call for Organogenesis Holdings Inc. At this time, all participants are placed in listen-only mode. seekingalpha.com 2024-08-09 03:08:06 Czytaj oryginał (ang.)
Organogenesis (ORGO) Reports Q2 Loss, Tops Revenue Estimates Organogenesis (ORGO) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.04 per share a year ago. zacks.com 2024-08-08 23:36:48 Czytaj oryginał (ang.)
Organogenesis Shares ReNu® Program Update CANTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced a development program update for ReNu®, a cryopreserved amniotic suspension allograft (ASA), for the management of symptoms associated with knee osteoarthritis (OA). globenewswire.com 2024-08-08 20:04:00 Czytaj oryginał (ang.)
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024 CANTON, Mass., July 15, 2024 (GLOBE NEWSWIRE) --  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that second quarter of fiscal year 2024 financial results will be reported after the market closes on Thursday, August 8th. globenewswire.com 2024-07-15 20:05:00 Czytaj oryginał (ang.)
Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference CANTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the Truist Securities MedTech Conference, which is being held at the InterContinental Boston in Boston, MA on Tuesday, June 18th. Management will participate in 1x1 meetings. There will be no formal presentation. globenewswire.com 2024-06-06 20:05:00 Czytaj oryginał (ang.)
Organogenesis Holdings, Inc. (ORGO) Q1 2024 Earnings Call Transcript Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Chair Dave Francisco - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Ross Osborn - Cantor Fitzgerald Drew Ranieri - Morgan Stanley Operator Welcome ladies and gentlemen to the First Quarter and Fiscal Year 2024 Earnings Conference Call for Organogenesis Holdings Inc. Please note, that this conference call is being recorded and the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A, Risk Factors, of the company's most recent annual report and a sequential filing with quarterly reports. seekingalpha.com 2024-05-10 01:01:02 Czytaj oryginał (ang.)
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis CANTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that its Phase 3 randomized control trial evaluating the safety and efficacy of ReNu, a cryopreserved amniotic suspension allograft (ASA), for the management of symptoms associated with knee osteoarthritis (OA) achieved its primary endpoint upon the analysis of positive top line data. globenewswire.com 2024-05-02 11:00:00 Czytaj oryginał (ang.)
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024 CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2024 financial results will be reported after the market closes on Thursday, May 9th. globenewswire.com 2024-04-16 11:30:00 Czytaj oryginał (ang.)
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that on March 29, 2024, the United States District Court for the Eastern District of New York granted, with prejudice, the Company's motion to dismiss all claims asserted. globenewswire.com 2024-04-03 11:30:00 Czytaj oryginał (ang.)
Why Organogenesis Holding Stock Plummeted by 18% Today To put it charitably, the market wasn't impressed with the company's recent performance. They traded out of the stock following the publication of quarterly and annual results. fool.com 2024-03-01 20:29:39 Czytaj oryginał (ang.)
Organogenesis Holdings, Inc. (ORGO) Q4 2023 Earnings Call Transcript Organogenesis Holdings, Inc. (ORGO) Q4 2023 Earnings Call Transcript seekingalpha.com 2024-03-01 01:06:09 Czytaj oryginał (ang.)